Introduction
MicroRNAs (miRNAs), an abundant class of small non-coding regulatory RNAs, are directly involved in various types of human and murine cancers and profoundly influence tumor development. [1] [2] [3] After initial transcription with several kilobases in length, primary miRNAs are cleaved by Drosha into B70-bp precursor miRNA in the nucleus. [4] [5] [6] Pre-miRNA is then exported to the cytoplasm and cleaved by Dicer into B22 nt mature miRNA. The latter is incorporated into the RNA-induced silencing complex, leading to translation inhibition by binding to the 3 0 -untranslational region (3 0 -UTR) of target mRNA. It is well accepted that the expression levels of miRNA are generally decreased in cancerous tissues than in corresponding normal tissues. [7] [8] [9] However, some miRNAs can also be overexpressed in cancers by acting as oncogenes or by negatively regulating tumor-suppressor genes and/or genes that control cell differentiation or apoptosis. 10 Thus, aberrant miRNA expression can be regarded as a common feature of cancers; identification of these dysregulated miRNAs and their respective targets may provide potential biomarkers for cancer diagnostics and new therapeutic strategies against cancer.
Leukemia is a consequence of abnormal regulation of lymphoid or myeloid commitment during hematopoiesis. The differential expressions of miRNAs in hematopoiesis suggest that deregulated miRNAs have potential roles in leukemogenesis. 11, 12 At present, the involvement of miRNAs in leukemogenesis has been established and several miRNAs including miR-155 and miR-17-92 clusters have been identified as oncogenic miRNAs in human leukemia. [13] [14] [15] [16] However, in the whole miRNA pool, other leukemic oncogenic miRNA(s) need to be identified.
miR-142-3p is originally identified as a hematopoieticspecific miRNA, 17 and expressed in various hematopoietic cell lineages. 18 In a recent report, it was found that miR-142-3p is aberrantly expressed in human T-cell lymphotropic virus type-1 (HTLV-1) adult T-cell leukemia. 19 In our previous study, we demonstrated that miR-142-3p restricts cyclic adenosine monophosphate (cAMP) production in conventional CD4 þ T cells by targeting adenylyl cyclase 9 mRNA. 20 Adenylyl cyclases catalyze ATP to cAMP; as a consequence, cAMP binds to and activates protein kinase A (PKA). It is well known that cAMP not only inhibits normal T-cell proliferation but also negatively regulate T-leukemia cells through the PKA pathway. 21, 22 Taken together, those findings implied that deregulation of miR-142-3p might contribute to leukemogenesis by decreasing cAMP levels and thus promoting T-leukemic cell growth. In addition, the miR-142-3p gene is at the breakpoint junction of a t (8;17) translocation, 23 which also implies a possible link of miR-142-3p to leukemogenesis. However, to date, whether miR-142-3p is involved in leukemogenesis remains unknown. In this study, we provided evidence that miR-142-3p has an oncogenic role in patients with T-cell acute lymphoblastic leukemia (T-ALL) by promoting leukemic cell growth and inducing resistance to glucocorticoid (GC) treatment. Our data showed that miR-142-3p specially targeted the cAMP/PKA pathway and glucocorticoid receptor alpha (GRa). These findings indicated that the upregulation of miR-142-3p is critical in T-cell leukemogenesis, which might open a new venue to develop effective strategies against T-ALL.
Materials and methods

Patients and cell lines
This study included 74 patients with confirmed T-ALL at present or in relapse. Their diagnosis was based on routine morphological evaluation, immunophenotyping and cytochemical smears using the French-American-British classification. In some patients, the prognosis was evaluated based on prednisone response, MRD analysis, sex, age, white blood cell count, morphological and immunological subtypes and cytogenetic change. Peripheral blood was obtained from patients and healthy volunteers. Informed consent was obtained from all patients in accordance with the Declaration of Helsinki and with approval of the Clinical Research Ethics Board of the Tongji Medical College and the Peking University People's Hospital.
Human acute T-lymphoblastic leukemia cell lines Jurkat, MOLT-3, MOLT-4 and CCRF/CEM were purchased from the ATCC (Manassas, VA, USA). Human hepatocarcinoma HepG2, cervical carcinoma HeLa and embryonic kidney 293T cell lines were purchased from the China Center for Type Culture Collection (CCTCC, Wuhan, China). Cells were cultured according to their guidelines.
Isolation of T-leukemic cells
Peripheral blood cells of patients were collected and separated by the Ficoll gradient centrifugation. The obtained peripheral blood mononuclear cells were used for T-leukemic cell purification by negative magnetic sorting with biotinylated anti-human CD14, CD16, CD19, CD36, CD56, CD123 and CD235a antibodies (Pan T-Cell Isolation Kit II, Miltenyi Biotec, Bergisch Gladbach, Germany). In addition, normal T cells were isolated from peripheral blood mononuclear cells of healthy volunteers.
Isolated primary T-leukemic cells were cultured in 35-mm Petri dishes at 37 1C, 5% CO 2 , in RPMI 1640 medium supplemented with 15% fetal calf serum, 20 mM HEPES, 200 Units/ml penicillin, 50 mg/ml streptomycin, 0.05 mM 2-mercaptoethanol (2-ME), 2 mM glutamine, 10 ng/ml phorbol 12-myristate 13-acetate (PMA) (all from Sigma, St Louis, MO, USA) and 10 ng/ml recombinant human interleukin-2 (Peprotech, Rocky Hill, NJ, USA).
Analysis of miR-142-3p by RT-PCR and quantitative RT-PCR
Total miRNAs were isolated from tumor cell lines using miRNA isolation kit (Ambion, Austin, TX, USA). Reverse transcription primers for miR-142-3p were designed with RNA mfold version 2.3 server and the analysis of miR-142-3p by reverse transcription-PCR (RT-PCR) and quantitative RT-PCR was conducted according to our previous study. 20 In brief, 100 ng of enriched miRNA was used for cDNA synthesis. A 67-bp cDNA product was amplified by PCR with the following primers: 5 0 -CTCCTGTAGTGTTTCCTAC-3 0 (sense) and 5 0 -GACT GTTCCTCTCTTCCTC-3 0 (antisense). For real-time PCR, the above primers and the Taqman probe (6-FAM)TTGCGACTA CACACACACACACA(BHQ1a-6FAM) were mixed with TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA). The reaction mixtures were incubated at 95 1C for 10 min, followed by 40 cycles of 95 1C for 15 s and 60 1C for 1 min in Stratagene quantitative RT-PCR instrument (Agilent Technologies, Santa Clara, CA, USA). The data were analyzed using the Delta Ct (cycle threshold) method.
Survival analysis
Overall survival or leukemia-free survival was calculated from the time of diagnosis until the date of death (censoring for live patients at the time of the last follow-up). We measured the expression of miR-142-3p in 68 T-ALL patients by quantitative RT-PCR. The levels of miR-142-3p were then converted into discrete variables by splitting the samples into two classes (high and low expressions, according to the median expression in all samples). Kaplan-Meier plots were used to display the association of miR-142-3p with disease outcome.
Transfection assay
Transfection assay was performed as described in our previous study. 20 In brief, miR-142-3p, miR-142-3p inhibitor, GRa smallinterfering RNA (siRNA) and the corresponding scrambled control oligonucleotides were purchased from RiboBio Corporation (Guangzhou, China). In brief, for transient transfection, 200 pmol of synthesized oligonucleotide was mixed with 100 ml of Nucleofector solution (Amaxa, Gaithersburg, MD, USA), and transfected into 5 Â 10 6 T-leukemic cells by electroporation using Nucleofector instrument. After transfection, cells were allowed to recover by incubating for 4 h at 37 1C, and then used for the following assays.
Identification of the specificity of miR-142-3p to GRa mRNA 0 -UTR, and inserted into pMIR-REPORT luciferase reporter vector (Sac I and Hind III restriction enzyme sites; Ambion). Another expressing vector was also constructed by the insertion of a mutated GRa 3 0 -UTR in which the target sequence of miR-142-3p was mutated into CACCACA using QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies). Recombinant reporter vectors with normal or mutated GRa 3 0 -UTR were then co-transfected with miR-142-3p into CHO cells using TransMessenger transfection reagent (Qiagen, Hilden, Germany). The luciferase assay was performed according to the previous study. 20 T-leukemic cell proliferation assay T-leukemic cell lines or isolated primary T-leukemic cells were transfected with miR-142-3p, miR-142-3p inhibitor and control oligonucleotide, respectively, using the Nucleofector instrument. Twenty-four hours later, cells were seeded in a 96-well plate (5 Â 103 per well) in the presence or absence of 0.5 mg/ml anti-CD3 and CD28 antibodies (R&D Systems, Minneapolis, MN, USA) or 20 ng/ml PMA and 200 ng/ml ionomycin (Sigma). Forty-eight hours later, T-cell proliferation was assayed using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell proliferation kit (Roche Diagnostics, Indianapolis, IN, USA) according to the manufacturer's instructions.
Western blot
Cell lysates (30 mg of total protein) and prestained molecular weight markers were separated by SDS-PAGE, followed by transfer onto nitrocellulose membranes. The membranes were blocked in TBST (Tris-buffered saline with 0.5% of Triton X-100) containing 5% non-fat milk, and probed with the primary antibody. After incubation with the secondary antibody miR-142-3p promotes T-leukemic cell growth M Lv et al conjugated with horseradish peroxidase, membranes were extensively washed, and immunoreactivity was visualized by enhanced chemiluminescence according to the manufacturer's protocol (ECL kit, Santa Cruz Biotechnology, Santa Cruz, CA, USA). All antibodies were purchased from Santa Cruz Biotechnology.
Apoptosis determination
T-leukemic cells were harvested 48 h after exposure to either 0.1% ethanol (as vehicle control) or 0.1 mM dexamethasone, then stained with phycoerithrin-Annexin V (BD Biosciences, San Diego, CA, USA) and analyzed by flow cytometry (BD LSR II). The proportion of apoptotic cells was calculated by Annexin-V þ cells/total cells.
Analysis of gene expression by RT-PCR and real-time RT-PCR
Cells were lysed with TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and total RNA was extracted according to the manufacturer's instructions. A RT-PCR procedure was used to determine the expression of mRNA (one-step RT-PCR kit; Qiagen). The primer sequences were as follows: GAPDH (glyceraldehyde 3-phosphate dehydrogenase), 5
0 (antisense). For real-time RT-PCR assays, cDNA sequences of all detected genes were retrieved from the NCBI database. 24 The primers were designed using the Oligo Primer Analysis 4.0 software (Molecular Biology Insights, Cascade, CO, USA), and sequences were blasted (http://www.ncbi.nlm.nih.gov/BLAST/). Total RNA (100 ng) was used for reverse transcription using Superscript II RNase H reverse transcriptase (Invitrogen) in a volume of 25 ml. Overall, 2 ml of cDNA was then amplified with SYBR Green Universal PCR Mastermix (Bio-Rad, Richmond, CA, USA) in duplicate. The resulting data were analyzed with the comparative Ct method for relative gene expression quantification against GAPDH.
Colony-forming assays
The colony-forming activity of T-leukemic cells was assayed using MethoCult H4434 (Stem Cell Technologies, Vancouver, BC, Canada) according to the manufacturer's instructions. In brief, T-leukemic cell lines were transfected with the miR-142-3p inhibitor or control oligonucleotide. Twenty-four hours later, cells were resuspended at 10 000 cells/ml of MethoCult methylcellulose-based media. All conditions were performed in triplicate at 37 1C and 5% CO 2 and colonies were counted 14 days later.
Statistics
Results were expressed as mean value±s.d. and interpreted by analysis of variance repeated-measures test. Differences were considered to be statistically significant when Po0.05.
Results
miR-142-3p is highly expressed in human T-leukemic cells
To look for the potential link between miR-142-3p and T-ALL, in this study, we first analyzed the expression of miR-142-3p in four human acute T-leukemic cell lines, namely Jurkat, MOLT-3, MOLT-4 and CCRF/CEM by RT-PCR. As shown in Figure 1a , a strong expression of miR-142-3p was detected in these four T-leukemic cell lines, but not in human hepatocarcinoma HepG2, cervical carcinoma HeLa or embryonic kidney 293T cell lines. Consistently, a similar result was observed by realtime RT-PCR ( Figure 1b ). To validate these data in vivo, we isolated normal T cells and T-leukemic cells from healthy volunteers and T-ALL patients, respectively. Real-time RT-PCR results indicated that although it is expressed in all T-cell samples from healthy volunteers (n ¼ 10), miR-142-3p is expressed at a significant higher level in T-leukemic cells from patients ( Figure 1c) . Moreover, for all samples, the Ct value ranged between 24 and 29. These 15 samples from T-ALL patients could be divided into 2 groups (9 with good prognosis and 6 with poor prognosis), based on the clinical analysis of patients' sex, age, white blood cell count, morphological and immunological subtypes, cytogenetic change and prednisone response. Interestingly, we found that samples from the poor prognosis group showed significant higher expression of miR-142-3p than did those from the good prognosis group (Figure 1c) . These data suggest that miR-142-3p might be a biomarker or have an important role in T-cell leukemia progression. Normal T cells and T-leukemic cells were isolated from healthy volunteers (n ¼ 10) and T-ALL patients (n ¼ 15), respectively, as described in the 'Materials and methods' section. Among 15 patents, 9 were with good prognosis and 6 were with poor prognosis. The levels of miR-142-3p in isolated cells were evaluated by real-time RT-PCR.
miR-142-3p promotes T-leukemic cell growth M Lv et al miR-142-3p is associated with the outcome of patients with T-ALL To verify whether the above data were of translational significance, we studied miR-142-3p expression in 68 T-ALL patients and its correlation with these patients' outcome. We split patients' samples into 2 classes (high and low expressions, according to the median expression in the whole set of 68 samples). The Kaplan-Meier survival data showed that patients with high expression of miR-142-3p had a significant shorter survival time than did those with a low expression of miR-142-3p (Figure 2a ). In addition, we also compared the expression of miR-142-3p between the above high and low two groups, and found that the expression of miR-142-3p was significantly different between them (Figure 2b) . Furthermore, based on the high or low expression of miR-142-3p, patient characteristics were summarized and statistically analyzed in Supplementary Table I , which showed that the expression of miR-142-3p was not correlated with sex, age, T-ALL sub-classification, cytogenetic abnormality or therapy. However, it was found that miR-142-3p expression indeed was correlated with relapse and leukemia-free survival (Figures 2c-d) . Taken together, these findings suggested that miR-142-3p is highly expressed in human T-leukemic cells and correlated with the outcome of T-cell leukemia patients.
miR-142-3p promotes T-leukemic cell proliferation but not apoptosis or self-renewal
Next, we speculated the role of miR-142-3p in T-leukemic cells. We previously reported that miR-142-3p targets adenylyl cyclase 9, leading to the decrease of intracellular cAMP. 20 Considering the inhibitory effect of cAMP on T-cell proliferation, 21 here, we hypothesized that miR-142-3p promoted T-leukemic cell proliferation. To test this, we transfected the miR-142-3p inhibitor to leukemia cells, and found that the inhibition of miR-142-3p activity significantly retarded the proliferation of either human T-leukemic cell lines or primary T-leukemic cells (Figure 3a, left; Supplementary Figure 1) . Moreover, transfection of the miR-142-3p inhibitor also impaired the stimulatory effect of anti-CD3/CD28 antibodies or PMA/ionomycin on leukemic cell proliferation (Figure 3a , middle). Interestingly, in line with improved T-leukemic cell proliferation, the levels of miR-142-3p were enhanced by stimulation of anti-CD3/CD28 antibodies or PMA/ionomycin (Figure 3a, right) . On the other hand, transfection of miR-142-3p resulted in the increased proliferation of T-leukemic cell lines or primary T-leukemic cells (Figure 3b, Supplementary Figure 2) . In addition to the effect on proliferation, we here also clarified whether miR-142-3p affected the apoptosis of T-leukemic cells. We used flow-cytometric analysis approach for this purpose, and found that inhibition of miR-142-3p did not affect apoptosis of T-leukemic cells (Figure 3c) . Consistently, the inhibition of miR-142-3p did not affect the expression of apoptosis-related genes Bcl-2, Bcl-xL, Bax and Bad in Jurkat cells, evaluated by real-time RT-PCR (Figure 3d) . Here, we also clarified whether miR-142-3p enhanced the self-renewal of T-leukemic cells. By performing a colony-forming assay, we found that inhibition of miR-142-3p activity had no effect on the colony-forming activity of T-leukemic cells (Figure 3e) . Therefore, these data suggested that miR-142-3p contributes to the proliferation, but has no direct effect on the apoptosis or self-renewal of T-leukemic cells.
miR-142-3p targets the cAMP/PKA pathway for leukemic T-cell proliferation Next, we explored the molecular mechanism through which miR-142-3p regulated T-leukemic cell proliferation. As a critical second messenger, cAMP induces the release of active catalytic subunits from cAMP-dependent PKA upon binding; consequently, the released subunits are translocated to the nucleus, leading to phosphorylation of various transcription factors. 24 We previously reported that miR-142-3p regulated the levels of cAMP in T cells; 20 here, we further tested the effect of miR-142-3p on the cAMP/PKA pathway in T-leukemic cells. Consistently, the transfection of miR-142-3p inhibitor significantly increased intracellular cAMP levels and cytosolic PKA activity in primary T-leukemic cells and in T-leukemic cell lines ( Figures 4a and b) ; and transfection of miR-142-3p reduced levels of cAMP and PKA activity (Figures 4a and b) . 8-BromocAMP and dibutyryl cAMP, cell-permeable cAMP analogs, are well known as the PKA activator; 25 Rp-cAMP, a diasteromer of cAMP, is a PKA inhibitor by competing with cAMP. 26 We found that the addition of either 8-bromo-cAMP or dibutyryl cAMP inhibited the promoting effect of miR-142-3p on T-leukemic cell proliferation ( Figure 4c) ; and addition of Rp-cAMP significantly attenuated the inhibitory effect of miR-142-3p inhibitor on T-leukemic cell proliferation (Figure 4d, Supplementary  Figure 3) . Taken together, these data suggested that miR-142-3p might regulate leukemic T proliferation through the cAMP/PKA pathway.
miR-142-3p targets GRa
MicroRNAs generally use their seed sequence to bind the 3 0 -UTR of various target mRNAs and exert regulatory function. Therefore, in addition to the above cAMP/PKA pathway, we here further investigated other potential targets of miR-142-3p, through which miR-142-3p affects the behavior of T-leukemic cells. By combinatorial utilization of three different algorithms, including TargetScan (http://www.targetscan.org/), PicTar (http://pictar.mdc-berlin.de/) and Sanger microRNA target (http://microrna.sanger.ac.uk/), we found that GR was a candidate target of miR-142-3p. This drew our attention for such reasons: (1) GCs are among the most important chemical drugs for T-cell leukemia treatment; 27 (2) GC resistance, the status of insensitivity of leukemic cells to GC, is a therapeutic problem with an incompletely clear molecular mechanism; 28 and (3) downregulation of GR has been believed to contribute to GC resistance. [29] [30] [31] Therefore, we hypothesized that the expression of GR in leukemic T cells was regulated by miR-142-3p. There are different mRNA transcripts of GR because of alternative splicing. Human GRa was recognized as the classical GR composed of a single polypeptide chain of 777 amino acids and is the primary mediator of GC action; in contrast, GRb is, although identical through amino acid 727, a negative mediator of GC action. 32 Interestingly, we found that miR-142-3p recognizing sequence (CACUACA) locates in GRa 3 0 -UTR, rather than GRb 3 0 -UTR. Thus, we focused on GRa. To confirm that GRa is the target of miR-142-3p, we transfected the miR-3p inhibitor into Jurkat cells, and found the inhibition of miR-142-3p strikingly increased GRa protein, but had no effect on GRa mRNA (Figure 5a ). On the other hand, transfection of miR-142-3p also had no effect on the expression of GRa mRNA, but resulted in a decrease of GRa protein (Figure 5a ). Taken miR-142-3p promotes T-leukemic cell growth M Lv et al together, these data suggested that miR-142-3p regulates the expression of GRa at the translational level but not at the transcriptional level.
Next, we clarified whether GRa was directly targeted by miR-142-3p. To test this, a luciferase reporter vector system was used and we found that the transfection of GRa 3 0 -UTR-containing luciferase reporter vector into CHO cells resulted in detection of luciferase activity. However, co-transfection of miR-142-3p and the reporter vector resulted in detection of a decreased luciferase activity (Figure 5b) . Thus, we concluded that miR-142-3p acts by directly targeting 3 0 -UTR of GRa.
miR-142-3p contributes to GC resistance of T-leukemic cells
Given the critical role of GRa expression in GC resistance, [29] [30] [31] miR-142-3p might be also involved in GC resistance through regulating GRa. Here, we further hypothesized that miR-142-3p regulated GC resistance in T-leukemic cells. To test this, we introduced the miR-142-3p inhibitor into T-leukemic cell lines and treated cells with dexamethasone, a synthetic active corticosteroid. We found that inhibition of miR-142-3p resulted in more cell death after dexamethasone treatment (Figure 6a ). To further uncover the link between miR-142-3p and GC resistance, we chose the CCRF/CEM cell line for GC-resistant cell clone screening. 30 After 10 days treatment with 0.1 mM dexamethasone, live cells were diluted into a 96-well plate with 100 cells/well for further selection. Consequently, four highly GC-resistant subclones were selected, in which 490% cells survived from dexamethasone treatment. As expected, upregulation of miR-142-3p in all four subclones was observed (Figure 6b) , and transfection of the miR-142-3p inhibitor resulted in 440% cell death, thus reversing GC resistance of these subclones (Figure 6c ). More importantly, we isolated T-leukemic cells from patients with a poor prednisone response (n ¼ 4) and also found that transfection of the miR-142-3p inhibitor promoted cell death induced by dexamethasone in all four patients (Figure 6d ). These data indicated an important role of miR-142-3p in GC resistance.
miR-142-3p induces GC resistance through targeting both GRa and cAMP/PKA pathways
The above data suggested that regulation of GC resistance by miR-142-3p might be through the GRa pathway. To provide more evidence, we adapted a comparable approach by silencing the GRa gene by using siRNA technology (Figure 7d ). We then transfected siRNA and the miR-142-3p inhibitor into Jurkat cells, and found that the knockdown of GRa could neutralize the effects of the miR-142-3p inhibitor on GRa expression (Figure 7a ). In addition, the PKA signaling pathway has been shown to be involved in the regulation of GC resistance. 32, 33 Considering that miR-142-3p also targeted the cAMP/PKA pathway (Figure 4 ), we here further tested whether regulation of GC resistance by miR-142-3p also involved the cAMP/PKA pathway. In line with this idea, we found that after GRa knockdown, transfection of the miR-142-3p inhibitor still partially reversed GC resistance of Jurkat leukemic cells (Figure 7b ), suggesting that miR-142-3p possibly regulates GC resistance beyond the GRa pathway. We then further transfected the miR-142-3p inhibitor or co-transfected the miR-142-3p inhibitor and GRa siRNA into Jurkat or CCRF/CEM cell line in the presence of dexamethasone and the PKA inhibitor Rp-cAMP. We found that interference of the PKA pathway by Rp-cAMP partly reversed the inhibitory effect of the miR-142-3p inhibitor on GC resistance ( Figure 7c) ; however, the interference of both PKA and GRa pathways in those cells by Rp-cAMP and GRa siRNA totally blocked the inhibitory effect of the miR-142-3p miR-142-3p promotes T-leukemic cell growth M Lv et al inhibitor on GC resistance (Figure 7c ). Taken together, these data suggested that both GRa and cAMP/PKA pathways are involved in the promotion of GC resistance by miR-142-3p.
Discussion
Roles of most miRNAs in leukemogenesis are still unclear, regardless of the identification of oncogenic properties for several individual miRNAs. In this study, we report that one individual miRNA, miR-142-3p, has an oncogenic role in leukemogenesis by promoting T-leukemic cell growth and enhancing GC resistance.
Several lines of evidence demonstrate that miR-142-3p is a critical regulator in T-cell differentiation and function, including Therefore, miR-142-3p probably intrinsically regulates the homeostasis of T cells. Its downregulation in effector T cells seems to avoid T-cell overactivation and the resultant autoimmunity. Thus, deregulation of miR-142-3p might result in abnormal T-cell proliferation and even in T-cell leukemogenesis. Supporting this idea, in this study, we find that stimulation of T-leukemic cells by anti-CD3/CD28 or PMA/ionomycin further increased the levels of miR-142-3p, regardless of its high basal expression. On the basis of the study by Wu et al. and our studies, 20, 34 an interesting question is why miR-142-3p is downregulated in normal T cells but upregulated in transformed T cells upon T-cell receptor stimulation. One possibility is that leukemic and normal T cells, upon T-cell receptor stimulation, differ in intracellular molecular events. For instance, certain transcription factors might be alternatively activated in T-leukemic cells, which recognize and bind the promoter region of miR-142-3p, thus promoting transcription. Nevertheless, elucidating such molecular mechanisms may not only strengthen our understanding of T-cell leukemogenesis but may also provide new insights into T-cell biology. Regardless of the aberrant expression of miR-142-3p in T-leukemic cells, an important finding is that the levels of miR-142-3p are correlated with prognosis in T-ALL patients. Such clinical data further emphasize the pivotal role of miR-142-3p in T-leukemic cells. Taken together, our data presented here suggest that miR-142-3p is critical in T-cell leukemogenesis, which may be a useful marker for evaluating the outcome of T-ALL patients.
The finding that miR-142-3p targets GC receptor GRa rather than GRb is very clinically important in this study. GCs remain a central component of the therapeutic armamentarium for a broad spectrum of hematological malignancies through binding to GR and inducing malignant cell apoptosis. 35 Despite the wide clinical usages of this type of drugs, failure of patients' leukemic cells to undergo GC-induced cell death causes a serious problem in clinical treatment. Although the mechanism is complicated, GR is considered a fundamental factor for the development of GC resistance. [29] [30] [31] Owing to the alternative splicing, the GR gene has multiple GR transcript isoforms, including active GRa and inhibitory GRb. 36 The latter can form heterodimer with GRa and inactivate GRa activity. 37 Therefore, both downregulation of GRa and upregulation of GRb may contribute to GC resistance. Although GR mutation may cause resistance, mutations in leukemic patients are rare and may not have a main role in GC resistance. 38 Tissing et al. 39 show that there is no difference in the degree of regulation of GR mRNA between GC-sensitive and GC-resistant leukemic samples upon GC exposure, indicating a possibility of posttranscriptional regulation of GR expression. Here, we demonstrate such possibility by miR-142-3p targeting the 3 0 -UTR of GR mRNA in T-ALL cells, including the Jurkat cell line. It has been reported that GC resistance in Jurkat cells might be attributed to the expression of one wild-type and one mutated GR allele and the mutation-induced impairment of the GR auto-induction regardless of the low basal levels of GR. 40 With regard to the abundant expression of miR-142-3p in T-leukemic cells (Figure 1) , the functional blockade of mir-142-3p by the inhibitor might augment the expression of GR and restore GR auto-induction. On the basis of our findings and that of others, we suggested that downregulation of GRa by miR-142-3p might be an important mechanism for GC resistance.
Regardless of our deciphering miR-142-3p in this study, how miR-142-3p is regulated in T-leukemic cells was not addressed. As a pleiotropic transcription factor, nuclear factor-kB (NK-kB) is known to be constitutively activated in T-leukemic cells 41 and capable of regulating miRNAs, such as miR-155 and miR-146. 42, 43 Coincidently, the NF-kB signaling pathway has been demonstrated to be involved GC resistance. 44, 45 These facts cause us to speculate the regulation of miR-142-3p by NF-kB. We analyzed the 5 0 -UTR of the miR-142-3p gene and indeed found the NF-kB-binding site in the sequence. Further elucidation of this regulatory mechanism is currently under study.
cAMP/PKA is the central signaling pathway, which may inactivate T cells through various pathways, including (1) inhibiting anti-CD3-induced mitogen-activated protein kinase activation by phosphorylating Raf-1; 46 (2) suppressing T-cell miR-142-3p promotes T-leukemic cell growth M Lv et al proliferation by downregulating cyclin D3 but upregulating p27 kip1 ; 47 (3) mediating the production of inducible cAMP earlyrepressor ICER; 48 and (4) interfering with the activation of the I kappa B kinase (IKK) complex, selectively suppressing the NFkB pathway. 49 Therefore, activation of the cAMP/PKA pathway may represent a potential strategy in T-leukemia therapeutics and inhibition of this pathway however may facilitate T-cell leukemogenesis. Thus, the limitation of the production of cAMP by miR-142-3p targeting adenylyl cyclase 9 20 hints a potential connection between miR-142-3p and T-cell leukemogenesis. In this study, we showed that miR-142-3p promotes T-leukemic cell proliferation by inhibiting the cAMP/PKA pathway. Moreover, cAMP/PKA has been reported to synergize with the GR signaling pathway to induce T-leukemic cell apoptosis. 32, 33 We here show that miR-142-3p attenuates both cAMP/PKA and GR signaling pathways. This may be the reason why targeting miR-142-3p can effectively convert GC resistance of T-leukemic cells. Taken together, these findings further emphasize the critical role of miR-142-3p in T-leukemia cells.
In summary, we find here that one individual miRNA, miR-142-3p, has an oncogenic role in T-cell leukemogenesis by targeting cAMP/PKA and GR, two essential signaling pathways. Therefore, the interference of miR-142-3p may represent a novel strategy in the therapeutics of T-ALL.
